Novatreat Ltd

Novatreat´s head quarters and the production facilities are located in the brand new Turku Biovalley. The main research facilities are located at the Helsinki Science Park.

The development work of immune milk products is a challenging process that requires good facilities and a network of collaborators. Being involved with the biocenters in both Turku and Helsinki puts us right at the heart of the latest developments in the field, giving at the same time an access to both the most advanced technology and the best expertise with great connections to both academic collaborators and authorities. Novatreat has at its disposal the services of excellent laboratories, animal facilities, process pilot plant and a close connection to some of the largest hospitals in Finland.

Novatreat Ltd. is a Finnish biotech company dedicated to becoming a leading developer and producer of immune milk products to be used in the fight against hospital infections. Hospital infections are a growing global problem. As bacteria are becoming increasingly resistant to antibiotics, serious infections have turned difficult to combat by using current chemotherapy. Novatreat´s immune milk products provide a novel approach by reducing the risk of hospital infections.

Immune milk products are derived from the colostrum of immunized cows and contain specific antibodies. The naturally occurring antibodies (immunoglobulins) in bovine colostrum are known to provide a major antimicrobial effect against a wide range of various pathogenic bacteria and viruses. In immune milk technology, the concentration of specific antibodies in colostrum is raised by immunizing mother cows with microbial vaccines. Such hyperimmune colostrum, immune milk, can give protection against various specific bacteria and viruses. Increasing attention is paid to the possibilities of exploiting bovine colostral antibodies for passive immunotherapy or prophylaxis of human gastrointestinal diseases. Novatreat´s first product will be an immunoglobulin concentrate against endemic hospital infections. Immune milk products benefit specially patients at high risk, such as cancer patients on high levels of medication and those in intensive care. In addition to specific antibodies, immune milk products contain non-specific immunoglobulins, other natural anti-microbial compounds and growth factors that improve the general health status of patients.